Poor Man, I also agree with biosectinvestor when he said that it makes sense to keep these CDMO salaries and capital expenditures off of NWBio's financial statements. If NWBio had a wholly-owned CDMO subsidiary, those costs would have to be reported by NWBio on its financial statements on a consolidated basis.
I do not see the NWBio / Cognate relationship as a conflict of interest. All NWBO shareholders have benefited from NWBio's relationships with Cognate and Advent. Whether they realize it or not.
Because of NWBio's relationships with Cognate and Advent, NWBio is on the verge of getting DCVax-L regulatory approvals in the US, UK, Canada, Germany and the rest of the EU.
Once these DCVax-L regulatory approvals are granted, NWBO shareholders will reap the benefit of gains of multiple billions of dollars in increased market cap. That will benefit all NWBO shareholders by increasing the value of all of our investment portfolios.
Market Data 
Markets 
AI
